Walter L. Binder

Nova Medical (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Gary L. Norman

North Carolina State University

Ernst H. Beutner

University at Buffalo, State University of New York

Zakera Shums

Nova Medical (United States)

Stefania Jabłońska

Medical University of Warsaw

Anǵela Tincani

University of Brescia

Laura Andréoli

University of Brescia

Tadej Avčin

Ljubljana University Medical Centre

Pier Luigi Meroni

University of Milan

Cecilia Nalli

University of Brescia

Mario Motta

Azienda USL di Bologna

Cooperative Institutions

Nova Medical (United States)

University at Buffalo, State University of New York

Hokkaido University

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Center for Rheumatology

University of Brescia

McMaster University

The University of Tokyo

Universidad del Salvador

Medical Research Council

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Standardized measurement of major immunoglobulin class (IgG, IgA, and IgM) antibodies to β2glycoprotein I in patients with antiphospholipid syndrome

Journal of Clinical Laboratory Analysis (1998)

Stephen J. Lewis L B Keil Walter L. Binder Vincent A. DeBari

Patients with the antiphospholipid syndrome (APS) have autoantibodies directed against epitopes on β2 glycoprotein I (β2GPI). We describe herein the performance characteristics of standardized enzyme-linked immunosorbent assays (ELISAs) for anti-β2GPI of the three major immunoglobulin classes: IgG, IgA, and IgM. All three assays generated highly linear standard curves (5 points, r ≥ 0.993 for each); precision was excellent both intra-assay and run-to-run, with coefficients of variation (CV) ranging from 2.3% to 6.6%. Values for IgG anti-β2GPI correlated strongly with those obtained by an earlier method (r = 0.80, P < 0.0001). A study group consisting of 203 healthy subjects was used to generate percentile-based reference intervals for all three classes of anti-β2GPI. APS subjects' anti-β2GPI were found to differ significantly (P < 0.0001 for each) for those of the control population. All three assays correlated well with β2GPI-dependent anticardiolipin antibody (aCL) measurements; IgG: r = 0.94 (P < 0.0001), for IgA: r = 0.82 (P < 0.001) and for IgM: r = 0.84 (P < 0.0001). We suggest that these ELISAs may provide valuable standardized measurements of IgG, IgA, and IgM anti-β2GPI. J. Clin. Lab. Ana. 12:293–297, 1998. © 1998 Wiley-Liss, Inc.

Immunoglobulin A

Immunoglobulin M

10.1002/(sici)1098-2825(1998)12:5<293::aid-jcla8>3.3.co;2-b

Cite

Citations (0)

A case of dermatitis herpetiformis with IgA endomysial antibodies but negative direct immunofluorescent findings

Journal of the American Academy of Dermatology (2000)

Ernst H. Beutner Richard D. Baughman Barry M. Austin Richard W. Plunkett Walter L. Binder

Tissue transglutaminase

Dermatitis herpetiformis

Dapsone

Endomysium

Gluten free

Immunoglobulin A

10.1016/s0190-9622(00)70284-2

Cite

Citations (11)

Comments on the paper by S. Kimura and T. Nishikawa (1980): A further study on the mechanism of deposition of plasma protein in psoriasis scales

Archives of Dermatological Research (1981)

E. H. Beutner Stefania Jabłońska Vasanth Kumar Walter L. Binder T. P. Chorzelska

Deposition

10.1007/bf00408237

Cite

Citations (2)

Quantitative Studies on Immunofluorescent Staining

International Archives of Allergy and Immunology (1980)

Walter L. Binder Ernst H. Beutner

Dialysis of fluorescein-conjugated antibodies at pH 5.8–6.0 can reduce unwanted nonspecific staining. Selective precipitation of highly fluoresceinated proteins in mildly acidic buffer is a simple technique which can produce a reagent with greatly improved nonspecific staining characteristics with little or no loss of antibody activity. This technique may be especially useful when fluorescent antibody tests are to be performed on tissues which have a high propensity for nonspecific staining such as skin.

10.1159/000232534

Cite

Citations (30)

Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study

Nephrology Dialysis Transplantation (2011)

Michael Mähler Antonella Radice Renato Alberto Sinico Jan Damoiseaux Andrea Seaman

Autoantibodies to the non-collagen region (NC1) of the alpha-3 subunit of collagen IV represent a serological hallmark in the diagnosis of Goodpasture's syndrome (GPS). The objective of our study was to carefully analyze the performance characteristics of a novel anti-glomerular basement membrane (GBM) chemiluminescence immunoassay (CIA). Sera from patients with GPS ( n = 90) were collected from four clinical centers. Samples from different disease groups ( n = 397) and healthy individuals ( n = 400) were used as controls. All samples were tested for anti-GBM antibodies by a rapid, random access CIA (QUANTA Flash™ GBM). Most of the samples were also tested using other methods including different commercial anti-GBM IgG assays and research assays for anti-GBM IgA and IgM. The sensitivity and specificity of the novel CIA was 95.6% [95% confidence interval (CI) 89.0–98.8%] and 99.6% (95% CI 98.9–99.9%), respectively. Receiver operating characteristic analysis showed good discrimination between GPS patients and controls. The area under the curve was 0.98 (CI 0.96–1.0). The three anti-GBM antibody-positive samples from the control group were from two healthy individuals and one human immunodeficiency virus (HIV)-infected patient. All three individuals had low levels of anti-GBM antibodies [20, 24 and 25 chemiluminescent unit (CU), cutoff 20 CU]. When the results of the new CIA were compared to other methods, good agreement was observed: 95.8% (kappa = 0.92) versus EliA™ GBM, 97.4% (kappa = 0.95) versus both BINDAZYME™ Anti-GBM and QUANTA Lite® GBM. Anti-GBM IgA was detectable in low concentrations in patients with GPS and was associated with anti-GBM IgG but was less useful in discriminating GPS patients and controls. No discrimination was found for anti-GBM IgM. The novel QUANTA Flash™ GBM CIA demonstrated good sensitivity and specificity and had good agreement with other methods. Our data confirm that ∼5% of patients with GPS do not have detectable levels of anti-GBM antibodies.

10.1093/ndt/gfr203

Cite

Citations (33)

Detection of IGA and IGG anti-human red blood cell tissue transglutaminase and diagnosis of celiac disease

Clinical and Applied Immunology Reviews (2002)

Suzanne K. Lewis Vicki J. Nelson Walter L. Binder

Tissue transglutaminase

Endomysium

Immunoglobulin A

Selective IgA deficiency

10.1016/s1529-1049(02)00078-8

Cite

Citations (0)

Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus

The Journal of Rheumatology (2013)

Ehtisham Akhter Zakera Shums Gary L. Norman Walter L. Binder Hong Fang

Objective. Currently, 3 antiphospholipid assays are widely used clinically [lupus anticoagulant (LAC), anticardiolipin (aCL), and anti-ß 2 -glycoprotein I (anti-ß 2 -GPI)]. LAC is the most specific assay, conferring the highest risk of thrombosis and pregnancy loss, but it cannot be validly performed in an anticoagulated patient. We investigated the usefulness of antiphosphatidylserine/prothrombin (anti-PS/PT) and its association with thrombosis. Anti-PS/PT is strongly associated with the presence of LAC. We also studied the association of IgA antiphospholipid isotypes and specific domains of ß 2 -GPI with thrombosis in systemic lupus erythematosus (SLE). Methods. Stored samples from patients with SLE, with and without past thrombosis, were assayed for antibodies to the whole ß 2 -GPI protein (IgG/IgM/IgA), to ß 2 -GPI domain 1 (IgG), to ß 2 -GPI domain 4/5 (IgA), aCL (IgG/IgM/IgA), and anti-PS/PT (IgG, IgM, and IgG/M). LAC was detected using the dilute Russell’s viper venom time (dRVVT) with confirmatory testing. Results. Anti-PS/PT IgG and IgG/M and anti-ß 2 -GPI IgG, IgM, and IgA were highly associated with a history of LAC by dRVVT (p < 0.0001). For all thrombosis, of the traditional ELISA assays, anti-ß 2 -GPI IgA, IgG, and aCL IgA were most associated. Anti-PS/PT IgG and IgG/M had a similar magnitude of association to the traditional ELISA. For venous thrombosis, of the traditional ELISA, anti-ß 2 -GPI (IgG and IgA), anti-PS/PT (IgG and IgG/M), and aCL IgA were associated. Again, anti-PS/PT (IgG and IgG/M) had the same magnitude of association as the traditional ELISA. For stroke, significant association was seen with anti-ß 2 -GPI IgA D4/5. Conclusion. In anticoagulated patients, where LAC testing is not valid, anti-PS/PT, either IgG or IgG/IgM, might serve as useful alternative tests to predict a higher risk of thrombosis. Anti-PS/PT antibodies were associated with all thrombosis and with venous thrombosis. IgA isotypes in secondary antiphospholipid syndrome are associated with thrombosis. Anti-ß 2 -glycoprotein domain 1 was not shown to be associated with thrombosis in SLE.

Lupus anticoagulant

Immunoglobulin A

10.3899/jrheum.120084

Cite

Citations (44)

Subpopulations of anti-β2glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β2glycoprotein I

Reumatismo (2011)

Laura Andréoli Cecilia Nalli Mario Motta Gary L. Norman Walter L. Binder

Objective: Anti-β2glycoprotein I antibodies (a-β2GPI) are a laboratory criterion for the antiphospholipid syndrome (APS) and were demonstrated to be involved in the pathogenesis of APS. However, they can also be detected in asymptomatic subjects. It has been suggested that a-β2GPI against Domain1 (D1) associate with thrombosis, while those recognizing Domain4/5 (D4/5) have been identified in non-thrombotic conditions. We evaluate the specificity of a- β2GPI in different clinical situations. Methods: We studied 39 one-year-old healthy children born to mothers with systemic autoimmune diseases (SAD) (15 (38.4%) were born to mothers who were a-β2GPI positive), 33 children with atopic dermatitis (AD) and 55 patients with APS (50 adults and 5 paediatrics). All subjects were IgG a-β2GPI positive. IgG a-β2GPI were performed by homemade ELISA, while IgG a-β2GPI D1 and D4/5 were tested on research ELISAs containing recombinant β2GPI domains antigens. Results: One-year-old children and AD children displayed preferential reactivity for D4/5; patients with APS recognized preferentially D1. We also found a good correlation between a-β2GPI and D4/5 in one-year-old (r=0.853) and AD children (r=0.879) and between a-β2GPI and D1 in the APS group (r=0.575). No thrombotic events were recorded in both groups of children. Conclusions: A-β2GPI found in non-thrombotic conditions (healthy children born to mothers with SAD and AD children) mostly recognize D4/5, in contrast to the prevalent specificity for D1 in the APS group. The different specificity could at least partially explain the “innocent” profile of a-β2GPI in children.

Pathogenesis

10.4081/reumatismo.2010.189

Cite

Citations (0)

In vitro effects of pemphigus antibodies on skin

British Journal of Dermatology (1978)

Walter L. Binder Ernst H. Beutner Tadeusz P. Chorzelski

Journal Article In vitro effects of pemphigus antibodies on skin Get access WALTER L. BINDER, WALTER L. BINDER Department of Microbiology, State University of New York at Buffalo, Buffalo, New York 14214, and Department of Dermatology, Warsaw Academy of Medicine, Warsaw, Poland Search for other works by this author on: Oxford Academic Google Scholar ERNST H. BEUTNER, ERNST H. BEUTNER Department of Microbiology, State University of New York at Buffalo, Buffalo, New York 14214, and Department of Dermatology, Warsaw Academy of Medicine, Warsaw, Poland Search for other works by this author on: Oxford Academic Google Scholar TADEUSZ P. CHORZELSKI TADEUSZ P. CHORZELSKI Department of Microbiology, State University of New York at Buffalo, Buffalo, New York 14214, and Department of Dermatology, Warsaw Academy of Medicine, Warsaw, Poland Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 99, Issue 1, 1 July 1978, Pages 39–42, https://doi.org/10.1111/j.1365-2133.1978.tb01958.x Published: 01 July 1978

10.1111/j.1365-2133.1978.tb01958.x

Cite

Citations (24)

Relevance of complement fixing antinuclear antibodies

International Journal of Dermatology (1999)

Yisheng Fang PhD. PhD.Stanley Cyran Boris Albini Rezvan Rostami

Abstract Background Connective tissue diseases (CTDs) are a heterogeneous group of disorders defined by the association of a variety of clinical manifestations with immunologic and other laboratory findings. Overlap of syndromes and aberrant findings appear rather frequently. Methods Sera of eight antinuclear antibody (ANA) negative, cases of subacute cutaneous lupus erythematosus (SCLE) with antibodies to Ro (SS‐A) and a ninth case with clinical and laboratory signs of Sjögren’s syndrome and systemic lupus erythematosus (SLE) were tested for complement (C′) fixing antinuclear antibodies (C‐ANAs). The ninth case was examined in depth by direct immunofluorescence (DIF) and a two‐step “C + DIF” test of biopsies for C′ fixation to in vivo bound ANAs, as well as serum tests for C‐ANA, ANA, and SCLE markers. Results Sera of five of the eight ANA negative, Ro(SS‐A) positive SCLE cases had C‐ANAs. The ninth case, a 50‐year‐old woman with clinical and laboratory signs of Sjögren’s syndrome and SLE, gave a strong positive C + DIF reaction in the skin biopsy for in vivo bound ANAs that fix C′, but negative ANAs and C‐ANAs in routine serum tests; they revealed antimitochondrial antibodies. Serum tests on normal skin, however, revealed weak ANA and strong C‐ANA reactions with in vitro fixed C′. Conclusions ANA negative cases of SCLE or Sjögren’s syndrome may have C‐ANAs. A case with Sjögren’s syndrome and signs of SLE had both in vivo and in vitro C′ fixing ANAs. C‐ANA tests can aid in the identification of such cases.

Complement fixation test

10.1046/j.1365-4362.1999.00580.x

Cite

Citations (3)